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INTRODUCTION
Success rate of in vitro fertilization depends on two
main things, namely the quality of the embryo and
the atmosphere of endometrium during implanta-
tion. Endometrium has two phases during each
menstrual cycle, which are proliferative and secre-
tion phase.1 Physiologic changes in endometrial lin-
ing consists of increased functional layer thickness
and increased spiral artery to prepare for implanta-
tion. If those changes fail to achieve pregnancy,
menses occur.2,3 Therefore, to facilitate a successful
pregnancy, an adequate growth of endometrium is
necessary.3,4
Several literatures stated the presence of a signifi-
cant relation between endometrial thickness with
pentoxifylline (PTX) therapy, however some failed
to show the effect. The thickness of endometrial
lining will improve the success rate of pregnancy in
assisted reproductive technology (ART).1,5
PTX is a phosphodiesterase inhibitor derived
from methylxanthine, a vasodilating chemical sub-
stance which can induce morphologic changes in
erythrocytes, prevent inflammation process, and re-
duce blood viscosity by preventing platelet aggrega-
tion process and increasing concentration of intra-
cellular cyclic nucleotide.6-9 Currently, PTX is used
as therapy for vascular problems, such as intermit-
tent claudication, ischemic ulcers and many more.8
This research was performed to evaluate the sig-
nificance of improvement in endometrial lining with
PTX as a single regimen therapy. In many developed
countries, PTX has entered clinical trials with pla-
cebo, providing a variety of results. Nowadays, ART
is beginning to develop in Indonesia, thus it is con-
sidered important to perform a direct evaluation of
PTX.
Abstract
Objective: To evaluate the effect of pentoxifylline as a single regimen
therapy for thin endometrial lining in infertility.
Method: A cross-sectional retrospective research was held in Yasmin
Clinic - Kencana, Dr. Cipto Mangunkusumo Hospital from 2010 un-
til 2011. Our respondents were women with infertility problem.
Result: There was significant improvement of endometrial lining in
respondents who received pentoxifylline in the first month
(p<0.0001).
Conclusion: There was significant improvement of endometrial lin-
ing after pentoxifylline therapy.
[Indones J Obstet Gynecol 2015; 3: 151-153]
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Abstrak
Tujuan: Menilai efek pentoksifilin sebagai terapi tunggal untuk dinding
endometrium tipis pada masalah infertilitas.
Metode: Penelitian potong-lintang retrospektif dilakukan di Klinik
Yasmin - RSCM Kencana sejak 2010 sampai 2011. Responden meru-
pakan perempuan dengan permasalahan infertilitas.
Hasil: Terdapat peningkatan tebal endometrium pada responden yang
mendapat pentoksifilin pada bulan pertama (p<0,0001).
Kesimpulan: Terdapat perbaikan bermakna pada dinding endometrium
setelah terapi pentoksifilin.
[Maj Obstet Ginekol Indones 2015; 3: 151-153]
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METHODS
This study was carried out in cross sectional design
involving 22 respondents, and took place in Yasmin
Clinic Kencana, Dr. Cipto Mangunkusumo Hospi-
tal from 2010 to 2011. Target population for this
study was patients presenting for infertility prob-
lems to Yasmin Clinic and fulfilled the inclusion cri-
teria. Inclusion criteria for our study were women
who agreed to join the study, patients with inferti-
lity, and patients with endometrial thickness <6
mm; while our exclusion criteria were those who
had pelvic inflammatory disease. We defined thin
endometrium as a condition where the functional
layer of endometrium during the secretory phase is
less than 6 mm in thickness, while no hormonal im-
balance or infections were identified from our exa-
minations.
Endometrial thickness was assessed using trans-
vaginal ultrasound at mid-luteal phase by a single
operator. The assessment was performed at baseline
before PTX therapy administration, then the pa-
tient’s endometrial thickness was reassessed in the
second and third month after receiving PTX con-
tinuously.
RESULT
Of the twenty-two samples collected, we found that
the patients’ age ranged from 29 to 44 years, with
a median of 36 years old. Most of the samples
(9.41%) had unexplained infertility, whereas we also
identified other causes such as endometrial polyps
(1.5%), IVF failure (1.4%), and polycystic ovaries
(1.5%).
Table 1. Age Characteristic Description




The endometrial thickness in the first month be-
fore administration of PTX ranged between 2.8-5
mm with a median value of 5 mm; while in the se-
cond month, the range is increased to 4-14 mm with
a median value of 7.0 mm; and in the third month
ranged between 4-12 mm with a median value of
8.0 mm. According to statistical calculations with
repeated measure method (Friedman), we obtained
a p-value of <0.0001, which shows the significance
between endometrial thickness before and after
PTX therapy. The study shows that endometrial
thickness increased in 18 respondents (82%) in the
second month, and continued to increase in 9 res-
pondents (41%) in the third month, while 1 respon-
dent experienced decrease in thickness. For endo-
metrial thickness in the second month compared to
the previous month in which the patient has not
received PTX treatment, we obtained a p-value
<0.0001; and for the third month to the second
month, we obtained p-value <0.0001.
In the first month of PTX therapy, 18 respon-
dents (82%) experienced an increase in endometrial
thickness and four respondents (18%) showed no
change in endometrial thickness. Meanwhile, in the
second to third months, nine respondents (41%)
showed improvement of endometrial lining, 12 res-
pondents had no change, and one respondent (5%)
actually had declining endometrial thickness.
Table 3. Endometrial Thickness Change in the First,
      Second and Third Month
1st and 2nd month
n(%)
2nd and 3rd month
n(%)
Increase 18 (82) 9 (41)
No change 4 (18) 12 (54%)
Decrease 0 (0) 1 (5%)
We encountered adverse effect in three patients,
with nausea and dizziness at the first week after
using pentoxyphiline. After receiving education and
observation, after two weeks the symptoms dis-
appeared.
Table 2. Endometrial Thickness in the First Month of Therapy (not yet receiving PTX), Second and Third Month
     (after receiving PTX)
1st month 2nd month 3rd month p-value
Endometrial thickness (mm) (median[min-max]) 5 (2.8 - 5) 7 (4 - 14) 8 (4 - 12) <0.0001
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DISCUSSION
The results obtained from our study, demonstrate
the significance of the relationship between endo-
metrial thickness before and after PTX therapy.
This can be explained because PTX supplementation
may increase cAMP function and decrease levels of
TNF-α which may improve the process of implan-
tation. Administration of PTX also results in in-
creased flexibility and decreased erythrocyte aggre-
gation of platelets, thereby increasing blood flow to
the small capillaries in the endometrium, the result
of which can be assessed from the thickness of the
endometrium.
PTX as a therapy regimen may provide potential
improvements affecting microvascularization, thus
repairing thin endometrium and also improving tis-
sue oxygenation.
CONCLUSION
PTX therapy significantly increases endometrial
thickness in patients with thin endometrium. PTX
can be used to improve the thickness of the en-
dometrium in these patients.
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